People · Operator
Named in public records as an officer, director or promoter · active 2017–2017 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Trillium Therapeutics Inc. | — | Pharmaceuticals | Series B | $20.0M | $679.2M | 2017 |
Helen Tayton-Martin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Helen Tayton-Martin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Moore | 1 | 12 |
| JAMES PARSONS | 1 | 6 |
| Robert Kirkman | 1 | 3 |
| Robert Uger | 1 | 2 |
| Thomas Reynolds | 1 | 2 |
| Niclas Stiernholm | 1 | 2 |
| Penka Petrova | 1 | 2 |
| Luke Beshar | 1 | 1 |
| Eric Sievers | 1 | 1 |
| Henry Frieson | 1 | 1 |
| Calvin Stiller | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.